Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Asia

    Quote from the article: Without adapting JCA to include assessment of real-world data and broader benefits, vaccines may be undervalued

    Is Joint Clinical Assessment (JCA) appropriate for assessing the broader value of vaccines?

    By Emily Morton-West

    Amiculum

    - PMLiVE

    A Call to Action: Bridging the Adult Immunization Divide

    Over the past few years, as new diseases have emerged or reemerged, a host of new vaccines have become available while many others are in the pipeline. For older adults,...

    Medscape Education

    - PMLiVE

    Sanofi and Kling Bio partner to accelerate discovery of neutralising antibodies

    The alliance will centre on Kling’s B cell immortalisation and screening platform Kling-Select

    - PMLiVE

    Webcast: China Update 2023: How will recent developments impact your brand’s success?

    Register for this live webinar in which emerging market experts provide an update regarding the implications of changing demographics and the healthcare landscape.

    Inizio

    Video: Strategic engagement case study

    Supporting the launch of a global vaccine with a programme of market research and strategic insights

    Inizio

    - PMLiVE

    WHO launches R&D efforts to identify pathogens that could cause future pandemics

    Over 300 scientists will convene to discuss over 25 virus and bacteria, including ‘Disease X’

    - PMLiVE

    CDC shows new BQ.1 and BQ 1.1 Omicron subvariants account for 44% of US COVID-19 cases

    The two new variants accounted for over 32% of US cases the prior week

    - PMLiVE

    Global leaders pledge $2.6bn at World Health Summit in efforts to end polio

    The pledging moment was a milestone in fulfilling the $4.8bn required to implement the GPEI Strategy

    - PMLiVE

    ONS data reveals significant decrease in COVID-19 antibodies

    The latest figures have prompted calls for the government to start its autumn booster vaccination campaigns as soon as possible

    - PMLiVE

    Moderna secures £1.74bn deal to supply US government with updated COVID-19 vaccine

    The company will supply 66 million doses of its COVID-19 vaccine booster updated for the Omicron subvariant

    - PMLiVE

    Mix-and-match COVID-19 vaccines may be more effective

    A small study shows a booster shot of J&J’s vaccine six months after a primary course of the Pfizer/BioNTech vaccine may offer more protection

    - PMLiVE

    Annual COVID-19 jabs likely, says Pfizer head

    Pfizer CEO predicts annual jabs will be needed to maintain a ‘very high level of protection’ against COVID-19 and emphasises the need to vaccinate children

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links